EndLyz Therapeutics
Boston, US · Founded 2021 · Delaware corporation · 7 employees on LinkedIn · 2 known investors
Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration. Its initial focus is genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other dementias.
Founders & leadership
JW
Joanna WolakExecutive
JB
Jonathan BehrNamed on SEC filing
JG
John GustofsonNamed on SEC filing
DC
Damian CrowtherNamed on SEC filing
ZK
Zaven KaprielianNamed on SEC filing
Board
LB
Laurence BarkerBoard director
JC
Justian Craig FoxBoard director
DL
Donmienne LeungBoard director
TE
Timothy EdwardsBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$20.5M disclosed across 2 rounds · 2021–2026
▶$17.3MraisedMay 2026 · 7 investors · OtherRule 506(b)
▶$17.3MraisedMay 2026 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
- Justian Craig FoxDirector
- Donmienne LeungDirector
- Laurence BarkerDirector
- Timothy EdwardsDirector
- Joanna WolakExecutive Officer, Director
- Offering amount
- $19.7M
- Amount sold
- $17.3M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedJul 2021 · 6 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJul 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan BehrDirector
- Joanna WolakExecutive Officer
- John GustofsonDirector
- Damian CrowtherDirector
- Zaven KaprielianExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $3.3M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Altay Therapeutics4 shared keywordsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
Amylyx4 shared keywordsAmylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
Xilio Therapeutics4 shared keywordsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Iolyx4 shared keywordsIolyx Therapeutics develops targeted immunomodulatory therapeutics for ocular inflammatory diseases at the intersection of immunology and ophthalmology, addressing conditions affecting both the front of the eye (such as dry eye, ocular allergies, and uveitis) and the back of the eye (such as age-related macular degeneration and diabetic retinopathy). The company aims to create alternatives to steroids and immunosuppressants with improved efficacy, safety, and convenience.
Lexeotx3 shared keywordsLEXEO Therapeutics develops gene therapy candidates aimed at genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. The clinical-stage company builds on research from Weill Cornell Medicine and the University of California San Diego.
Elicio3 shared keywordsElicio develops cancer immunotherapies including vaccines, immunomodulators, and adjuvants built on its lymph node-targeted AMP platform to activate and amplify cancer-fighting T cells. The company focuses on treating solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC).
Outlook Therapeutics3 shared keywords
Exelixis3 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with EndLyz Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does EndLyz Therapeutics do?
- Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration. Its initial focus is genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other dementias.
- Who are EndLyz Therapeutics's investors?
- EndLyz Therapeutics's investors include Oxford Science Enterprises, Dementia Discovery Fund.
- How much funding has EndLyz Therapeutics raised?
- EndLyz Therapeutics has disclosed $20.5M raised across 2 rounds.
- Where is EndLyz Therapeutics headquartered?
- EndLyz Therapeutics is headquartered in Boston, US.